New drug 'major step forward' for prostate cancer

A new type of hormone inhibitor could soon be available to prescribe for men with metastatic prostate cancer.

Patients with metastatic hormone-refractory prostate cancer currently have few treatment options.
Patients with metastatic hormone-refractory prostate cancer currently have few treatment options.

Centocor Ortho Biotech has applied to the European Medicines Agency for authorisation to market abiraterone, which blocks androgen synthesis by inhibiting the enzyme CYP17 (also known as 17α-hydroxylase/17,20 lyase).

The licence application includes data from the COU-AA-301 study, in which patients who received abiraterone survived 35% longer than those who took placebo.

Study investigators randomised 1,195 men with castration-resistant prostate cancer to undergo treatment with abiraterone 1g once daily or placebo, in addition to low-dose prednisolone/prednisone. All participants had been previously treated with docetaxel. Results of the study were presented at the 35th ESMO congress in Milan on 11 October 2010.

Compared with placebo, abiraterone extended median survival from 10.9 months to 14.8 months (p<0.00001). Patients who received abiraterone also showed a prolonged time to PSA progression, extended radiographic progression-free survival and an increased rate of PSA response.

"This should be considered a major step forward in prostate cancer therapeutics," said lead investigator Johann de Bono, from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London. "These results are likely to be practice-changing for men with advanced prostate cancer that has progressed on docetaxel-based chemotherapy, which has been a critical unmet need."

Mineralocorticoid-related adverse events were more common with abiraterone than placebo, with fluid retention occurring in 30.5% (versus 22.3%) of patients and hypokalaemia in 17.1% (versus 8.4%).

Two other treatments are generating further hope for patients with this hard-to-treat form of prostate cancer. The personalised immunotherapy sipuleucel-T (Provenge) is currently in Phase 3 trials and the microtubule inhibitor cabazitaxel (Jevtana) is awaiting European approval.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...